University of California Los Angeles - Gonda (Goldschmied) Diabetes Center
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yuen, Kevin C
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
Heaney, Anthony
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
Czerwiec, Frank
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
Mallavaraou, Samhita
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25

Download Options